Tumor volumes increased in an early phase in response to anti-CCL2 Ab treatment but rapidly reverted over time and resulted in the inhibition of primary tumor growth, suggesting that CCL2 neutralization may act in a biphasic manner. The gene discussed is CCL2; the disease is neoplasm.